TEMPEST THERAPEUTICS INC
COM · CUSIP 87978U108
* Summed across managers. Shares that two managers' reports both contain – a subsidiary's holdings that its parent's report includes too, or a sub-adviser's in its client's – are counted once. Holder counts are more reliable. Implied quarter-end price ≈ $1.11.
Trends to Q2 2026
Institutional holders
Managers reporting a position, each quarter
Numbers
| Quarter | Holders |
|---|---|
| Q3 2022 | 17 |
| Q4 2022 | 14 |
| Q1 2023 | 18 |
| Q2 2023 | 23 |
| Q3 2023 | 25 |
| Q4 2023 | 33 |
| Q1 2024 | 31 |
| Q2 2024 | 25 |
| Q3 2024 | 29 |
| Q4 2024 | 36 |
| Q1 2025 | 23 |
| Q2 2025 | 1 |
| Q3 2025 | 1 |
| Q4 2025 | 1 |
| Q1 2026 | 1 |
| Q2 2026 | 1 |
Buyers vs sellers
Managers adding to or starting a position, vs cutting or selling out
Numbers
| Quarter | Bought or added | Cut or sold out |
|---|---|---|
| Q3 2024 | 12 | 8 |
| Q4 2024 | 20 | 11 |
| Q1 2025 | 11 | 13 |
| Q2 2025 | 1 | 23 |
| Q3 2025 | 0 | 0 |
| Q4 2025 | 0 | 0 |
| Q1 2026 | 0 | 0 |
| Q2 2026 | 0 | 0 |
Major shareholders (over 5%)
Anyone who owns more than 5% of a class of the company's shares has to say so: on Schedule 13D if they may try to influence or control the company, on 13G if they're a passive investor, and update it as the stake changes. Each holder's latest filing, from 19 Dec 2024 on; percentages are of the share class, as the holder worked them out.
No one currently above 5% in the filings since 19 Dec 2024.
Fell to 5% or below in the last year: Versant Venture Capital VI, L.P. (1.1%, 2026-04-02)
Holders, Q2 2026
| Manager | Shares | Change |
|---|---|---|
| Versant Venture Management, LLC 0.18% of their portfolio | 269.8k $299.4k | Unchanged |